G D'Souza1, T S McNeel2, C Fakhry3. 1. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore. 2. Information Management Services, Inc., Calverton. 3. Department of Otolaryngology - Head and Neck Surgery, Johns Hopkins University, Baltimore, USA.
Abstract
BACKGROUND: Incidence of human papillomavirus (HPV)-related oropharyngeal cancer is increasing. There is interest in identifying healthy individuals most at risk for development of oropharyngeal cancer to inform screening strategies. PATIENTS AND METHODS: All data are from 2009 to 2014, including 13 089 people ages 20-69 in the National Health and Nutrition Examination Survey (NHANES), oropharyngeal cancer cases from the Surveillance, Epidemiology, and End Results (SEER 18) registries (representing ∼28% of the US population), and oropharyngeal cancer mortality from National Center for Health Statistics (NCHS). Primary study outcomes are (i) prevalence of oncogenic HPV DNA in an oral rinse and gargle sample, and (ii) incident oropharyngeal squamous cell cancer. RESULTS: Oncogenic oral HPV DNA is detected in 3.5% of all adults age 20-69 years; however, the lifetime risk of oropharyngeal cancer is low (37 per 10 000). Among men 50-59 years old, 8.1% have an oncogenic oral HPV infection, 2.1% have an oral HPV16 infection, yet only 0.7% will 'ever' develop oropharyngeal cancer in their lifetime. Oncogenic oral HPV prevalence was higher in men than women, and increased with number of lifetime oral sexual partners and tobacco use. Men who currently smoked and had ≥5 lifetime oral sexual partners had 'elevated risk' (prevalence = 14.9%). Men with only one of these risk factors (i.e. either smoked and had 2-4 partners or did not smoke and had ≥5 partners) had 'medium risk' (7.3%). Regardless of what other risk factors participants had, oncogenic oral HPV prevalence was 'low' among those with only ≤1 lifetime oral sexual partner (women = 0.7% and men = 1.7%). CONCLUSIONS: Screening based upon oncogenic oral HPV detection would be challenging. Most groups have low oncogenic oral HPV prevalence. In addition to the large numbers of individuals who would need to be screened to identify prevalent oncogenic oral HPV, the lifetime risk of developing oropharyngeal caner among those with infection remains low.
BACKGROUND: Incidence of human papillomavirus (HPV)-related oropharyngeal cancer is increasing. There is interest in identifying healthy individuals most at risk for development of oropharyngeal cancer to inform screening strategies. PATIENTS AND METHODS: All data are from 2009 to 2014, including 13 089 people ages 20-69 in the National Health and Nutrition Examination Survey (NHANES), oropharyngeal cancer cases from the Surveillance, Epidemiology, and End Results (SEER 18) registries (representing ∼28% of the US population), and oropharyngeal cancer mortality from National Center for Health Statistics (NCHS). Primary study outcomes are (i) prevalence of oncogenic HPV DNA in an oral rinse and gargle sample, and (ii) incident oropharyngeal squamous cell cancer. RESULTS: Oncogenic oral HPV DNA is detected in 3.5% of all adults age 20-69 years; however, the lifetime risk of oropharyngeal cancer is low (37 per 10 000). Among men 50-59 years old, 8.1% have an oncogenic oral HPV infection, 2.1% have an oral HPV16 infection, yet only 0.7% will 'ever' develop oropharyngeal cancer in their lifetime. Oncogenic oral HPV prevalence was higher in men than women, and increased with number of lifetime oral sexual partners and tobacco use. Men who currently smoked and had ≥5 lifetime oral sexual partners had 'elevated risk' (prevalence = 14.9%). Men with only one of these risk factors (i.e. either smoked and had 2-4 partners or did not smoke and had ≥5 partners) had 'medium risk' (7.3%). Regardless of what other risk factors participants had, oncogenic oral HPV prevalence was 'low' among those with only ≤1 lifetime oral sexual partner (women = 0.7% and men = 1.7%). CONCLUSIONS: Screening based upon oncogenic oral HPV detection would be challenging. Most groups have low oncogenic oral HPV prevalence. In addition to the large numbers of individuals who would need to be screened to identify prevalent oncogenic oral HPV, the lifetime risk of developing oropharyngeal caner among those with infection remains low.
Authors: Maura L Gillison; Tatevik Broutian; Robert K L Pickard; Zhen-you Tong; Weihong Xiao; Lisa Kahle; Barry I Graubard; Anil K Chaturvedi Journal: JAMA Date: 2012-01-26 Impact factor: 56.272
Authors: Dana Holzinger; Gunnar Wichmann; Lorena Baboci; Angelika Michel; Daniela Höfler; Manuel Wiesenfarth; Lea Schroeder; Paolo Boscolo-Rizzo; Christel Herold-Mende; Gerhard Dyckhoff; Andreas Boehm; Annarosa Del Mistro; Franz X Bosch; Andreas Dietz; Michael Pawlita; Tim Waterboer Journal: Int J Cancer Date: 2017-04-04 Impact factor: 7.396
Authors: Mona Saraiya; Elizabeth R Unger; Trevor D Thompson; Charles F Lynch; Brenda Y Hernandez; Christopher W Lyu; Martin Steinau; Meg Watson; Edward J Wilkinson; Claudia Hopenhayn; Glenn Copeland; Wendy Cozen; Edward S Peters; Youjie Huang; Maria Sibug Saber; Sean Altekruse; Marc T Goodman Journal: J Natl Cancer Inst Date: 2015-04-29 Impact factor: 13.506
Authors: Anil K Chaturvedi; Eric A Engels; Ruth M Pfeiffer; Brenda Y Hernandez; Weihong Xiao; Esther Kim; Bo Jiang; Marc T Goodman; Maria Sibug-Saber; Wendy Cozen; Lihua Liu; Charles F Lynch; Nicolas Wentzensen; Richard C Jordan; Sean Altekruse; William F Anderson; Philip S Rosenberg; Maura L Gillison Journal: J Clin Oncol Date: 2011-10-03 Impact factor: 44.544
Authors: Gypsyamber D'Souza; Yuehan Zhang; Samantha Merritt; Dorothy Gold; Hilary A Robbins; Victoria Buckman; Jennifer Gerber; David W Eisele; Patrick Ha; Joseph Califano; Carole Fakhry Journal: Oral Oncol Date: 2016-07-17 Impact factor: 5.337
Authors: Christine M Pierce Campbell; Aimée R Kreimer; Hui-Yi Lin; William Fulp; Michael T O'Keefe; Donna J Ingles; Martha Abrahamsen; Luisa L Villa; Eduardo Lazcano-Ponce; Anna R Giuliano Journal: Cancer Prev Res (Phila) Date: 2015-01-09
Authors: Ahmedin Jemal; Edgar P Simard; Christina Dorell; Anne-Michelle Noone; Lauri E Markowitz; Betsy Kohler; Christie Eheman; Mona Saraiya; Priti Bandi; Debbie Saslow; Kathleen A Cronin; Meg Watson; Mark Schiffman; S Jane Henley; Maria J Schymura; Robert N Anderson; David Yankey; Brenda K Edwards Journal: J Natl Cancer Inst Date: 2013-01-07 Impact factor: 13.506
Authors: Daniel C Beachler; Tim Waterboer; Christine M Pierce Campbell; Donna J Ingles; Krystle A Lang Kuhs; Alan G Nyitray; Allan Hildesheim; Michael Pawlita; Aimée R Kreimer; Anna R Giuliano Journal: Papillomavirus Res Date: 2016-07-28
Authors: Gypsyamber D'Souza; Gwendolyn Clemens; Tanya Troy; Rachel G Castillo; Linda Struijk; Tim Waterboer; Noemi Bender; Phillip M Pierorazio; Simon R Best; Howard Strickler; Dorothy J Wiley; Robert I Haddad; Marshall Posner; Carole Fakhry Journal: Cancer Prev Res (Phila) Date: 2019-08-16
Authors: Helen C Stankiewicz Karita; Amalia Magaret; Meei-Li Huang; Keith R Jerome; Quinne Feng; Anna Wald Journal: Sex Transm Dis Date: 2020-02 Impact factor: 2.830
Authors: Melina J Windon; Tim Waterboer; Alexander T Hillel; Wade Chien; Simon Best; Charles Stewart; Lee Akst; Tanya Troy; Noemi Bender; Brett Miles; William R Ryan; Rajarsi Mandal; Karen Pitman; David W Eisele; Carole Fakhry; Gypsyamber D'Souza Journal: Hum Vaccin Immunother Date: 2019-03-19 Impact factor: 3.452
Authors: Babatunde Y Alli; Robert D Burk; Mahnaz Fatahzadeh; Julie Kazimiroff; Robert M Grossberg; Richard V Smith; Thomas J Ow; Mauricio Wiltz; Jacqueline Polanco; Marie-Claude Rousseau; Belinda Nicolau; Nicolas F Schlecht Journal: J Infect Dis Date: 2020-07-23 Impact factor: 5.226
Authors: Melina J Windon; Gypsyamber D'Souza; Tim Waterboer; Lisa Rooper; William H Westra; Tanya Troy; Drew Pardoll; Marietta Tan; Siddhartha Yavvari; Ana P Kiess; Brett Miles; Wojciech K Mydlarz; Patrick K Ha; Noemi Bender; David W Eisele; Carole Fakhry Journal: Head Neck Date: 2020-02-26 Impact factor: 3.147
Authors: Virginia E Drake; Carole Fakhry; Melina J Windon; C Matthew Stewart; Lee Akst; Alexander Hillel; Wade Chien; Patrick Ha; Brett Miles; Christine G Gourin; Rajarsi Mandal; Wojciech K Mydlarz; Lisa Rooper; Tanya Troy; Siddhartha Yavvari; Tim Waterboer; Nicole Brenner; David W Eisele; Gypsyamber D'Souza Journal: Cancer Date: 2021-01-11 Impact factor: 6.860